The Goldman Sachs Group upgraded shares of Hypera (OTCMKTS:HYPMY – Get Rating) from a neutral rating to a buy rating in a research report released on Monday morning, The Fly reports.

Hypera Price Performance

Shares of HYPMY stock opened at $8.89 on Monday. Hypera has a 1 year low of $4.63 and a 1 year high of $9.17. The firm has a fifty day moving average price of $8.40 and a 200-day moving average price of $7.96.

Get Hypera alerts:

Hypera Company Profile

(Get Rating)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Read More

• Get a free copy of the StockNews.com research report on Hypera (HYPMY)
• Biogen's Stock Pullback Offers a Second Chance
• Pitch a Tent in Camping World Stock
• Fisker is Entering a Critical Stage That Could Reward Investors
• The Bottom Is In For JPMorgan Chase & Co.
• The Institutions May Cap Gains In Steel Dynamics

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.